Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, Douglas L., Greene, Stephen J., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Ambrosy, Andrew P., Shah, Palak, McNulty, Steven E., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., Mohammed, Selma F., Gilotra, Nisha A., DeVore, Adam D., Gorodeski, Eiran Z., Desvigne-Nickens, Patrice, Hernandez, Adrian F., Braunwald, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by the American College of Cardiology Foundation. Published by Elsevier. 2020
Materias:
Focus Issue: Angiotensin-Neprilysin Inhibition: Novel Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286640/
https://www.ncbi.nlm.nih.gov/pubmed/32641226
http://dx.doi.org/10.1016/j.jchf.2020.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286640/
https://www.ncbi.nlm.nih.gov/pubmed/32641226
http://dx.doi.org/10.1016/j.jchf.2020.05.005

Ejemplares similares